StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 Dyes Conjugated to Highly Validated Antibodies for Multicolor Panel Design in Immunology Research
HERCULES, Calif. — August 10, 2022 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today extended its range of StarBright Dyes to provide greater flexibility in multicolor flow cytometry panels. The StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 Dyes offer improved brightness with narrow excitation and emission profiles for precise resolution.
The Bio-Rad range of StarBright Dyes provides researchers with highly stable, validated flow antibodies conjugated to proprietary fluorescent nanoparticles and specific to key immunophenotyping targets, supporting multiplex flow cytometry panels in immunology research. Minimal lot-to-lot variation ensures reproducible and consistent staining, and the dyes are resistant to photobleaching and do not lose signal in fixation. The dyes, excited by violet (405 nm) and ultraviolet (355 nm) lasers, are compatible with the Bio-Rad ZE5 Cell Analyzer and S3e Cell Sorter, as well as most flow cytometers and a variety of experimental protocols, without the need for special buffers.
“The continued expansion of the Bio-Rad StarBright Dye portfolio, currently totaling 17 dyes, nine of which are StarBright Violet Dyes, gives researchers greater flexibility and choice when designing flow cytometry panels, by providing high-performance dyes excitable at a range of wavelengths,” said Mike Blundell, PhD, Bio-Rad Product Manager, Flow Cytometry, Life Science Group. “The exceptional brightness and unique profile of the dyes delivers enhanced resolution of rare populations and low-density antigens.”
To learn more about Bio-Rad StarBright Dyes, visit bio-rad-antibodies.com/flow-cytometry-starbright-dyes.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 7,900 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, supply chain risks, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contact:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
510-356-7909
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@zymecommunications.com
To opt out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com. To view our privacy policy, click here.
